This study is looking at how well the antibiotic telavancin gets into the brain and spinal fluid (cerebrospinal fluid or CSF) of critically ill patients. These patients have had a type of bleeding in the brain called a subarachnoid hemorrhage (SAH) and have a special drain (external ventricular drainage or EVD) to help manage fluid around the brain. Researchers want to see if telavancin reaches high enough levels in the CSF to fight infections. You might be able to join if you are an adult between 18 and 85 years old, have an EVD, and meet other health requirements. The study aims to enroll 20 participants and will measure telavancin levels over 3 days.

Study design

This is a prospective cohort study, meaning researchers will follow a group of patients over time. It aims to include 20 participants.

What's involved

You would receive telavancin intravenously (through a vein) once a day for 3 days. Blood and CSF samples will be taken during this time.

Compensation

Not stated in the trial record.

Follow-up

Telavancin levels will be measured for 3 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.